UniSuper Management Pty Ltd Sells 10,080 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

UniSuper Management Pty Ltd cut its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 57.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,499 shares of the company’s stock after selling 10,080 shares during the quarter. UniSuper Management Pty Ltd’s holdings in IDEXX Laboratories were worth $3,100,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in IDXX. FSA Wealth Management LLC bought a new position in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter worth $31,000. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $38,000. Finally, Crews Bank & Trust bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Stock Down 1.6 %

Shares of IDXX opened at $415.87 on Friday. The firm has a market cap of $33.71 billion, a P/E ratio of 38.98, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The stock has a 50 day simple moving average of $437.07 and a two-hundred day simple moving average of $442.90.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent analyst reports. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, March 25th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Finally, Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.